1st Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Int J Mol Sci. 2024 May 14;25(10):5372. doi: 10.3390/ijms25105372.
Heart failure (HF) poses a significant world health challenge due to the increase in the aging population and advancements in cardiac care. In the pathophysiology of HF, the inflammasome has been correlated with the development, progression, and complications of HF disease. Discovering biomarkers linked to inflammasomes enhances understanding of HF diagnosis and prognosis. Directing inflammasome signaling emerges as an innovative therapeutic strategy for managing HF. The present review aims to delve into this inflammatory cascade, understanding its role in the development of HF, its potential role as biomarker, as well as the prospects of modulating inflammasomes as a therapeutic approach for HF.
心力衰竭（HF）是一个全球性的健康挑战，由于人口老龄化和心脏治疗的进步，这个问题变得更加严重。在 HF 的病理生理学中，炎症小体与 HF 疾病的发展、进展和并发症相关。发现与炎症小体相关的生物标志物可以增强对 HF 诊断和预后的理解。靶向炎症小体信号传递成为管理 HF 的一种创新治疗策略。本综述旨在深入探讨这一炎症级联反应，了解其在 HF 发展中的作用、作为生物标志物的潜在作用，以及调节炎症小体作为 HF 治疗方法的前景。
Zotero 插件